

RECEIVED
CENTRAL FAX CENTER

AUG 12 2007

COVER PAGE LISTING DOCUMENTS BEING TRANSMITTED VIA FACSIMILE

13 Pages Via Facsimile: 571-273-8300
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Certificate of Transmission

I hereby certify that this correspondence is being facsimile transmitted to the U.S. Patent and Trademark Office (fax no. 571-273-8300) on August 1, 2007.

Stephen Bulkstein
Stephen Bulkstein

Regarding the following Application:

Applicant(S): STEINER, Mitchell S. Examiner: Fuhara, Blessing M
et al.

Serial No./ 10/747,686 Group Art Unit: 1618
Patent No.:

Filed/Issued Date: December 30, 2003 Attorney Docket No.: P-2769-US9

Title: A METHOD FOR CHEMOPREVENTION OF PROSTATE CANCER

Please find:

- | | |
|--|---|
| 1. <input type="checkbox"/> Provisional Cover Sheet | 9. <input type="checkbox"/> Response to Notice to File Missing Parts |
| 2. <input type="checkbox"/> Utility Patent Application Transmittal | 10. <input type="checkbox"/> Response to Notice of Incomplete Reply |
| 3. <input type="checkbox"/> RCE Transmittal Sheet | 11. <input type="checkbox"/> Request for Correction of Filing Receipt |
| 4. <input type="checkbox"/> Fee Transmittal Sheet | 12. <input checked="" type="checkbox"/> Information Disclosure Statement including:
- Form PTO/SB/08 and references _____ |
| 5. <input type="checkbox"/> Patent Application Under 35 USC 111(a) | 13. <input type="checkbox"/> Preliminary Amendment |
| <input type="checkbox"/> Provisional Patent Application Under 35 USC 111(b) | 14. <input type="checkbox"/> Response to Office Action
dated _____ |
| <input type="checkbox"/> Transmittal Sheet for Entering National Phase
Containing: | 15. <input type="checkbox"/> Petition for a One Month(s) Extension of Time |
| _____ Pages of Specification | 16. <input type="checkbox"/> Notice of Appeal <input type="checkbox"/> Appeal Brief _____ |
| _____ Pages of Claims | 17. <input type="checkbox"/> Issue Fee Transmittal <input type="checkbox"/> Publication Fee |
| _____ Page of Abstract | 18. <input type="checkbox"/> Submission of Formal Drawings: Two sets of
_____ Sheets containing Figs. _____ |
| _____ Pages of Formal Drawings | 19. <input type="checkbox"/> Copy of Priority Doc. |
| _____ Pages of _____ | 20. <input type="checkbox"/> Claim for Convention Priority |
| 6. <input type="checkbox"/> Signed Declaration & Power of Attorney | 21. <input type="checkbox"/> Revocation and Power of Attorney, including:
- Statement Under 37 CFR 3.73(b)
- Copy of Assignment |
| 7. <input type="checkbox"/> Request for Correction of Recordation of Assign. and:
- Recordation Cover Sheet
- Copy of Notice of Recordation of Assign. | 22. <input type="checkbox"/> Other: _____ |
| 8. <input type="checkbox"/> Recordation of Assign. Cover Sheet & Signed Assign. | |

APPLICANT'S: STEINER, Mitchell S. et al.
SERIAL NO.: 10/747,686
FILED: December 30, 2003
Page 2

The information herein cited is only in fulfillment of Applicant(s) duty of candor in disclosing all information brought to Applicant(s) attention. This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art". If it should be determined that any of the listed documents do not constitute "prior art" under United States law, Applicant(s) reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant(s) further reserve(s) the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each and every document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application and is evidence that the Examiner has considered the document.

This Information Disclosure Statement is being filed:

- I) ☐ Within three (3) months of filing the subject Application or entry of the subject Application into the national stage or before mailing of the first Office Action on the merits of the subject Application or a request for continued examination thereof, whichever event occurs last pursuant to 37 C.F.R. §1.97 (b); or
- II) ☒ After the period specified in (I) but before the mailing date of either a final Official Action under 37 C.F.R. §1.113 or a notice of allowance under 37 C.F.R. §1.311 whichever occurs first and;

1. ☐ the undersigned hereby states that each item of information listed on the Form PTO-1449 was either (i) cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this Information Disclosure Statement or (ii) not cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, not known to any individual designated in §1.56(c) more than three (3) months prior to the filing of this information disclosure statement; or

APPLICANTS:
SERIAL NO.:
FILED:
Page 3

STEINER, Mitchell S. et al.
10/747,686
December 30, 2003

RECEIVED
CENTRAL FAX CENTER
AUG 02 2007

2. ☒ the undersigned hereby authorizes the Patent Office to charge the fee in the amount of \$180.00 under 37 C.F.R. §1.17 (p) to Deposit Account 50-3355.

III) ☐ After the period in (I) and (II) but before the payment of the issue fee and,

1. The undersigned hereby states:

a) ☐ that each item of information cited on the form PTO-1449 was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three (3) months prior to the filing of this Information Disclosure Statement; or

b) ☐ that no items of information contained in Form PTO-1449 was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; and

2. ☐ The undersigned hereby authorizes the Patent Office to charge the Petition fee in the Amount of \$180.00 under 37 C.F.R. §1.17 (p) to Deposit Account 50-3355.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-3355.

Respectfully submitted,

Mark S. Cohen
Attorney for Applicants
Registration No. 42,425

Dated: August 1, 2007

PEARL COHEN ZEDEK LATZER LLP
1500 Broadway, 12th Floor
New York, NY 10036
Phone: (646) 878-0800
Fax: (646) 878-0801

AUG 02 2007

Please type a plus sign (+) inside this box ?

+

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/747,686
		Filing Date	December 30, 2003
		First Named Inventor	STEINER, Mitchell S.
		Group Art Unit	1615
		Examiner Name	Not yet known
Sheet	1	of	9
		Attorney Docket Number	P-2769-US9

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A	4,990,538		Harris et al.	February 5, 91	
	B	5,788,964		Baral et al.	August 4, 98	
	C	5,650,425		Biegnon et al.	July 22, 97	
	D	4,696,949		Toivola et al.	Sept 29, 87	
	E	5,491,173		Toivola et al.	Feb. 13, 1996	
	F	5,571,534		Jalonen et al.	Nov. 5, 1996	
	G	5,605,700		DeGregorio et al.	Feb. 25, 1997	
	H	5,595,722		Grainger et al.	Jan. 21, 1997	
	I	5,599,844		Grainger et al.	Feb. 4, 1997	
	J	5,629,007		Audia et al.	May 13, 1997	
	K	5,635,197		Audia et al.	June 3, 1997	
	L	5,595,985		Labrie	Jan. 21, 1997	
	M	5,441,988		Thompson, et al	08-15-1995	
	N	5,852,059		Thompson, et al	12-22-1998	
	O	5,827,892		Loeser, et al	10-27-1998	
	P	5,821,254		Sporn, et al	10-13-1998	
	Q	5,859,045		Treppendahl, et al	01-12-1999	
	R	5,935,987		Treppendahl, et al	08-10-1999	
	S	2005/0171073		Steiner, et al	01-2006	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴ (if known)			
	T	WO	98/58634		December 30, 98	
	U	EP	415 623 A2	Harris et al	March 6, 1991	
	V	EP	616 529 B1		September 28, 94	
	W	EPC	095875		Dec 7, 1995	
	X	WO	95/26720	Biegon et al	Oct 12, 1995	
	Y	WO	0008001		Feb 17, 2000	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box ?

+

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0851-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/747,888
		Filing Date	December 30, 2003
		First Named Inventor	STEINER, Mitchell S.
		Group Art Unit	1615
		Examiner Name	Not yet known
Sheet	2 of 8	Attorney Docket Number	P-2769-US9

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite. No. ¹	U.S. Patent Document Number Kind Code ² (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	Z	4,329,364		Neri et al.	May 11, 1982	
	AA	4,474,813		Neri et al.	Oct. 2, 1984	
	AB	6,080,877		Swindell et al	June, 2000	
	AC	6,265,448		Steiner et al	July 24, 2001	
	AD	6,410,043		Steiner et al	June 25, 2002	
	AE	6,632,447		Steiner et al	Oct 14, 2003	
	AF	6,413,533		Steiner et al	July 2, 2002	
	AG	6,413,534		Steiner et al	July 2, 2002	
	AH	6,413,535		Steiner et al	July 2, 2002	
	AI	4,996,225		Toivola et al	Feb 26, 1991	
	AJ	5,811,120		Gibson et al	Sept 22, 1998	
	AK	5,972,383		Gibson et al	Oct 26, 1999	
	AL	4,418,068		Jones	Nov 29, 1983	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite. No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	AM	WO	94/12162		Warri et al	June 9, 1994		<input type="checkbox"/>
	AN	WO	99/56739		Steiner et al	November 11, 1999		<input type="checkbox"/>
	AO	WO	00/47214		Healey et al	August 17, 2000		<input type="checkbox"/>
	AP	WO	96/09046		Audia et al	March 28, 1996		<input type="checkbox"/>
	AQ	EP	0 670 162		Gibson et al	Sept 6, 1995		<input type="checkbox"/>
	AR	WO	00/19998		KGK Synergize	04-13-2000		<input type="checkbox"/>
	AS	WO	97/25038		Novo Nordisk	7-17-1997		<input type="checkbox"/>
	AT	WO	99/08682		Duke University	02-25-1999		<input type="checkbox"/>
	AU	WO	97/25037		Novo Nordisk	7-17-1997		<input type="checkbox"/>

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box ?

+

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/747,888
		Filing Date	December 30, 2003
		First Named Inventor	STEINER, Mitchell S.
		Group Art Unit	1615
		Examiner Name	Not yet known
Sheet	3	of	9
		Attorney Docket Number	P-2769-US9

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AV	Greenwald "Expanding Horizons in Breast and Prostate Cancer Prevention and Early Detection", in J. Cancer Education, 1993, Vol. 8, No. 2, pages 91-107.	<input type="checkbox"/>
	AW	Brawley et al., "Chemoprevention of Prostate Cancer" in Urology, 1994, Vol. 43, No. 5.	<input type="checkbox"/>
	AX	Kelloff et al., "Introductory Remarks: Development of Chemopreventive Agents for Prostate Cancer" in Journal of Cellular Biochemistry, 1992, Supplement 1611: 1-8.	<input type="checkbox"/>
	AY	Lucia et al., "Chemopreventive Activity of Tamoxifen, N-(4-Hydroxyphenyl)retinamide, and the Vitamin D Analogue Ro24-5531 for Androgen-promoted Carcinomas of the Rat Seminal Vesicle and Prostate" in Cancer Research, 1995, vol. 55, pages 5621-5627.	<input type="checkbox"/>
	AZ	Potter et al., "A Mechanistic Hypothesis for DNA Adduct Formation By Tamoxifen Following Hepatic Oxidative Metabolism" in Carcinogenesis, 1994, Vol. 15, No. 3, pages 439-442.	<input type="checkbox"/>
	BA	Schneider Martin R. et al. "Nonsteroidal Antiestrogens and Partial Estrogens with Prostatic Tumor Inhibiting Activity", Cancer Research Clinical Oncology Springer-Verlag 1986, J Cancer Res Clin Oncol (1986) 112: 258-265, p. 258-265,	<input type="checkbox"/>
	BB	Martel Celine et al. "Binding Characteristics of Novel Nonsteroidal Antiestrogens to the Rat Uterine Estrogen Receptors", Pergamon, J. Steroid Biochem. Molec. Bio. Vol 64, No. 3-4, pp. 199-205, 1998.	<input type="checkbox"/>
	BC	Valavaara Ritva, MD, PhD "Reliability of Estrogen Receptors in Predicting Response To Antiestrogens", Oncology, Volume 11 Number 5 Supplement No. 4 p. 14-18.	<input type="checkbox"/>
	BD	Richard Gams, MD "Phase III Trials of Toremifene vs Tamoxifen" Oncology Volume 11, Number 5, Supplement 4, May 1997	<input type="checkbox"/>
	BE	Christian Rohlf et al. "Prostate Cancer Cell Growth Inhibition by Tamoxifen Is Associated With Inhibition of Protein Kinase C and Induction of p21" The Prostate 37:51-59 (1998) ©1998 Wiley-Liss, Inc	<input type="checkbox"/>
	BF	Nevalaninc et al. "Hormone Regulation of Human Prostate in Organ Culture" Cancer Res., vol. 53, no. 21, 1993, pages 5199-5207, X0002117653.	<input type="checkbox"/>
	BG	Gingrich et al., "Androgen-independent Prostate Cancer Progression in the TRAMP Model", in Cancer Research 57, November 1, 1997, pages 4687-4691.	
	BH	Gingrich et al., "Pathologic Progression of Autochthonous Prostate Cancer in the TRAMP Model", Prostate Cancer and Prostatic Diseases, 1999, 2, Pages 70-75.	
	BI	Gingrich et al., "Metastatic Prostate Cancer in a Transgenic Mouse", in Cancer Research 56, September 15, 1996, pages 4096-4102.	
	BJ	Gershonovich et al., "A Phase III Comparison of Two Toremifene Doses to Tamoxifen in Postmenopausal Women with Advanced Breast Cancer", Breast Cancer Research and Treatment 45, 1997, Pages 251-262.	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box ?

+

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/747,686
		Filing Date	December 30, 2003
		First Named Inventor	STEINER, Mitchell S.
		Group Art Unit	1615
		Examiner Name	Not yet known
Sheet	4	of	8
		Attorney Docket Number	P-2769-US9

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BK	Hayes et al. "Randomized Comparison of Tamoxifen and Two Separate Doses of Toremifene in Postmenopausal Patients with Metastatic Breast Cancer", Journal of Clinical Oncology, Vol. 13, No. 10, 1995, pages 2556-2566.	
	BL	Pyrhonen et al., "Comparison of Toremifene and Tamoxifen in Postmenopausal Patients with Advanced Breast Cancer: a Randomized Double-blind, the Nordic Phase III Study", British Journal of Cancer, 1997, 76(2), pages 270-277.	
	BM	Neubauer et al., "Endocrine and Antiproliferative Effects of Raloxifene (LY156758) in the Male Rat", The Prostate 23, 1993, pages 245-262.	
	BN	Pollard, "Prevention of Prostate-Related Cancers in Lobund-Wistar Rats", The Prostate 39, 1999, pages 305-309.	
	BO	Simard et al., "Keoxifene Shows Pure Antiestrogenic Activity in Pituitary Gonadotrophs", Molecular and Cellular Endocrinology 39, 1985, pages 141-144.	
	BP	Perry "High Dose Toremifene for Estrogen and Progesterone Receptor Negative Metastatic Breast Cancer: a Phase II Trial of the Cancer and Leukemia Group B (CALGB)", in Breast Cancer Res Treat - 1995; 26(1): 25-40	
	BQ	Hietanen T "Open Phase II Study of High-Dose Toremifene as First-Line Therapy for Advanced Breast Cancer" in Oncology - May 1997; 11(5 Suppl 4): 37-40.	
	BR	Black et al. "Uterine Bioassay of Tamoxifen, Trioxifene and a New Estrogen Antagonist (LY117018) in Rats and Mice" in Life Sciences, 1980, Vol. 26, pp. 1453-1458	
	BS	Moore et al. "Regulation of Cytoplasmic Dihydrotestosterone Binding in Dog Prostate by 17 β -Estradiol", in J. Clin. Invest. © The American Society for Clinical Investigation, Inc., Vol. 63 March 1979, pages 351-357.	
	BT	Shirai et al. "Effects of Testosterone, Dihydrotestosterone and Estrogen on 3,2'-Dimethyl-4-Aminobiphenyl-Induced Rat Prostate Carcinogenesis" in Int. J Cancer: 57, 224-228 (1994)	
	BU	Greenwald et al. "Breast Cancer Prevention and Early Detection", pages 93-106.	
	BV	Shenfield et al. "Androgen Deprivation Therapy", Chapter 37, Section III/Prostate Cancer, pages 467-477	
	BW	Jordan VC "Toremifene As An Anticancer Agent", Cancer Invest 1990; 8(2) 271	
	BX	Karlsson S. et al. "A Two-Year Dietary Carcinogenicity Study Of The Antiestrogen Toremifene In Sprague-Dawley Rats" Drug Chem Toxicol 1996 Nov; 19(4): 245-66.	
	BY	Powles TJ "Status Of Antiestrogen Breast Cancer Prevention Trials" Oncology (Huntingt) 1998 Mar; 12(3 Suppl 5): 28-31.	
	BZ	Moon RC et al. "Chemoprevention of MNU-Induced Mammary Tumorigenesis by Hormone Response Modifiers: Toremifene, RU 16117, Tamoxifen, Aminoglutethimide and Progesterone", Anticancer Res 1994 May-June; 14(3A): 889-93.	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box ?

+

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0851-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/747,686
		Filing Date	December 30, 2003
		First Named Inventor	STEINER, Mitchell S.
		Group Art Unit	1615
		Examiner Name	Not yet known
Sheet	8	of	9
		Attorney Docket Number	P-2769-US9

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Nevalainen MT et al. "Expression and Hormone Regulation Of Prolactin Receptors in Rat Dorsal and Lateral Prostate", Endocrinology 1996 Jul; 137(7): 3078-88.	
	CB	Peekens JA et al. "Expression Of Prostate-Specific Antigen (PSA) Correlates With Poor Response To Tamoxifen Therapy In Recurrent Breast Cancer", Br J Cancer 1999 Feb; 79(5-6): 888-94.	
	CC	Brandes LJ et al. "Salutary Clinical Response Of Prostate Cancer To Antiandrogen Withdrawal: Assessment Of Flutamide In An In Vitro Paradigm Predictive Of Tumor Growth Enhancement", Clin Cancer Res 1997 Aug; 3(8): 1357-61.	
	CD	Miyata E et al. "Effects Of Tamoxifen, An Antiestrogen, On Rat Prostate Carcinogenesis by 3,2'-Dimethyl-4-Aminobiphenyl And Testosterone Do Not Support An Estrogen Role In Testosterone Promotion", Prostate 1997 Apr 1;31(1)9-13.	
	CE	Pienta KJ et al. "A Phase II Evaluation Of Oral Tamoxifen And Intermittent Intravenous Vinblastine In Hormone-Refractory Adenocarcinoma Of The Prostate", Am J Clin Oncol 1996 Oct; 19(5):500-3.	
	CF	Pienta KJ et al. "Inhibition Of Prostate Cancer Growth By Vinblastine And Tamoxifen", Prostate 1995 May; 26(5): 270-4.	
	CG	Lippman SM et al. "Cancer Chemoprevention", J Clin Oncol 1994 Apr; 12(4):851-73.	
	CH	Szarka CE et al. "Chemoprevention Of Cancer", Curr Probl Cancer 1994 Jan-Feb; 18(1):6-79.	
	CI	Bergan RC et al. "A Phase II Study Of High-Dose Tamoxifen In Patients With Hormone-Refractory Prostate Cancer." Clin Cancer Res 1999 Sep; 5(9): 2366-73.	
	CJ	Chang William Y et al. "Estrogen Receptor-? : Implications For The Prostate Gland" The Prostate 40:115-124 (1999)	
	CK	Shughrue Paul J. et al. "Comparative Distribution Of Estrogen Receptor-? (Er-?) And ? (Er-?) mRNA In The Rat Pituitary, Gonad, And Reproductive Tract" Steroids 63: 498-504, 1998, Elsevier Science Inc.	
	CL	Prins Gail S. et al, "Neonatal Estrogen Exposure Up-Regulates Estrogen Receptor Expression In The Developing And Adult Rat Prostate Lobes*", Endocrinology 138: 1801-1809, 1997)	
	CM	Hempstock J. et al. "Growth Inhibition Of Prostate Cell Lines In Vitro By Phyto-Oestrogens", British Journal Of Urology (1998). 82. 560-563.	
	CN	Awoniyi Caleb A. et al. "Neonatal Exposure To Coumestrol, A Phytoestrogen, Does Not Alter Spermatogenic Potential In Rats", Endocrine, vol. 7, no. 3, 337-341, December 1997.	
	CO	"Chemoprevention Of Prostate Cancer: Guidelines For Possible Intervention Strategies", Journal of Cellular Biochemistry, Supplement 1611:140-145 (1992).	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

* **EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box ?

+

PTO/SB/08A (10-98)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/747,688
		Filing Date	December 30, 2003
		First Named Inventor	STEINER, Mitchell S.
		Group Art Unit	1615
		Examiner Name	Not yet known
Sheet	8	of	9
		Attorney Docket Number	P-2769-US9

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ²	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CP	"When Is Intervention Warranted?", Journal Of Cellular Biochemistry, Supplement 161:138-139 (1992).	
	CQ	"Editorial: A New Actor In The Estrogen Receptor Drama-Entre ER-?", Endocrinology Vol. 138, No. 3, (1997).	
	CR	Kulper George G. J. M. et al. "Comparison Of The Ligand Binding Specificity And Transcript Tissue Distribution Of Estrogen Receptors α and β ", Endocrinology Vol. 138, No. 3, 863-870 (1997).	
	CS	Colletta Anthony A. et al. "Alternative Mechanisms Of Action Of Anti-Oestrogens" Breast Cancer Research and Treatment 31: 5-9, 1994.	
	CT	Griffiths K. et al. "Further Insights Into Endocrine Disease - Diet and Prostate Disease" An IPHC Teaching Programme.	
	CU	Yu H et al. "Induction Of Prostate Specific Antigen Production By Steroids And Taxoxifen In Breast Cancer Cell Lines", Breast Cancer Res Treat 1994; 32(3):291-300.	
	CV	Horton J et al. "Tamoxifen In Advanced Prostate Cancer: An ECOG Pilot Study", Prostate 1988; 12(2):173-7.	
	CW	Kangas L "Development And Biochemical Pharmacology Of Toremifene, An Antiestrogenic Antitumor Drug", Acta Obstet Gynecol Scand 1991; 70(4-5): 399.	
	CX	Anttila M et al. "Pharmacokinetics Of The Novel Antiestrogenic Agent Toremifene In Subjects With Altered Liver And Kidney Function" Clin Pharmacol Ther 1995 Jun; 57(6):628-35.	
	CY	Kamat AM et al. "Chemoprevention Of Urological Cancer", The Journal Of Urology, Vol. 161. 1748-1760. June 1999, p. 1748-1760.	
	CZ	Fleton SA "Potential New Antiestrogens For The Treatment Of Breast Cancer", Highlights in Oncology Practice Vol. 15, No. 2, 1997 p. 47-52	
	DA	Nevalainen M.T. et al. "Estrogen and Prolactin Regulation of Rat Dorsal and Lateral Prostate in Organ Culture", Endocrinology, Vol. 129, No. 2 pages 612-618	
	DB	Moon R.C. et al. "Chemoprevention of MNU-Induced Mammary Tumorigenesis by Hormone Response Modifiers: Toremifene, RU 16117, Tamoxifen, Aminoglutethimide and Progesterone", Anticancer Research 14: 889-894 (1994)	
	DC	Price K. R. et al. "Naturally Occurring Oestrogens in Food - A review", Food Additives and Contaminants, 1985, Vol. 2, No. 2, 73-106.	

Examiner Signature	Date Considered
---------------------------	------------------------

* **EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box ?

+

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0851-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/747,686
		Filing Date	December 30, 2003
		First Named Inventor	STEINER, Mitchell S.
		Group Art Unit	1615
		Examiner Name	Not yet known
Sheet 7 of 9	Attorney Docket Number	P-2769-US9	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	DD	Cheng E et al. "Endocrinology Of The Prostate", Prostate Diseases, chapter 5- p. 57-71.	
	DE	Bonkhoff H et al. "Estrogen Receptor Expression In Prostate Cancer and Premalignant Prostatic Lesions", American Journal of Pathology, Vol. 155, No. 2 August 1999.	
	DF	"New Research Approaches In The Prevention And Cure Of Prostate Cancer", American Association For Cancer Research, December 1998	
	DG	Xiaolin Zi et al. "Silibinin Decreases Prostate-Specific Antigen With Cell Growth Inhibition Via G1 Arrest, Leading To Differentiation Of Prostate Carcinoma Cells: Implications For Prostate Cancer Intervention", Proc. Natl. Acad. Sci. USA Vol. 96, pp. 7490-7495, June 1999. Medical Sciences.	
	DH	Landstrom M, et al. "Inhibitory Effects Of Soy and Rye Diets On The Development Of Dunning R3327 Prostatic Adenocarcinoma In Rats, The Prostate 36: 151-161 (1998).	
	DI	Buelke-Sum J. et al. "The Selective Estrogen Receptor Modulator, Raloxifene: An Overview Of NonClinical Pharmacology And Reproductive And Developmental Testing", Reprod Toxicol 1998 May-June; 12(3):217-21.	
	DJ	Treinen KA et al. "An Evaluation Of The Novel Selective Estrogen Receptor Modulator, Idoxifene, For Effects On Reproduction In Rats And Rabbits", Toxicol Sci 1998 Feb; 41(2):199-207.	
	DK	Boehm S et al. "Estrogen Suppression As A Pharmacotherapeutic Strategy In The Medical Treatment Of Benign Prostatic Hyperplasia: Evidence For Its Efficacy From Studies With Meparticin" Wien Klin Wochenschr 1998 Dec 11; 110(23):817-23.	
	DL	Dhar JD et al. "Estrogen, Androgen and Antiestrogen Responses In The Accessory Organs Of Male Rats During Different Phases Of Life", Endocr Res 1998 May; 24(2): 159-69.	
	DM	West Neal B et al. "Estrogen and Progesterone Receptors And Aromatase Activity In Rhesus Monkey Prostate" Endocrinology, Vol. L. 123, (1998)	
	DN	Strauss L "Genistein Exerts Estrogen-Like Effects In Male Mouse Reproductive Tract", Molecular and Cellular Endocrinology 144 (1998) 83-93, Elsevier Science Ireland Ltd.	

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box ?

+

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/747,686
		Filing Date	December 30, 2003
		First Named Inventor	STEINER, Mitchell S.
		Group Art Unit	1616
		Examiner Name	Not yet known
Sheet	8	of	9
		Attorney Docket Number	P-2769-US9

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	DO	Hobisch Alfred "Metastatic Lesions From Prostate Cancer Do Not Express Oestrogen And Progesterone Receptors" J. Pathol. 182: 356-361, 1997.	
	DP	Albert David S. et al. "An Overview Of Clinical Cancer Chemoprevention Studies With Emphasis On Positive Phase III Studies" Overview of Diet Cancer 6928-6975 (1995)	
	DQ	Strom Sara S. et al. "Phytoestrogen Intake and Prostate Cancer: A Case-Control Study Using A New Database", Nutrition and Cancer, 33(1), 20-25. (1999).	
	DR	Kellof GJ et al.. "Strategies For Chemoprevention Of Prostate Cancer", Prostate Cancer and Prostate Disease (1988) 5. 107.	
	DS	Buelke-Sam Judy et al. "The Selective Estrogen Receptor Modulator, Raloxifene: An Overview Of NonClinical Pharmacology and Reproductive Development Testing", Reproductive Toxicology Vol. 12, No. 3 pp. 217-221, 1998.	
	DT	Prins Gail S. "Developmental Estrogenization Of The Prostate Gland", Prostate: Basic and Clinical Aspects p. 245-263 (1997).	
	DU	Kuiper George G. J. M. "Cloning Of A Novel Estrogen Receptor Expressed In Rat Prostate And Ovary", Proc. Natl. Acad. Sci USA Vol. 93, pp. 5925-5930, June 1996 Biochemistry.	
	DV	Kuiper George G. J. M. "Interaction Of Estrogenic Chemicals and Phytoestrogens With Estrogen Receptor ?", Endocrinology Vol. 139, No. 10 (1998).	
	DW	Horton John et al. "Tamoxifen In Advanced Prostate Cancer" An EOCG Pilot Study", The Prostate 12: 173-177 (1988).	
	DX	Hayes "A Randomized Comparison Of Tamoxifen, Trioxifene And A New Estrogen Antagonist (LY117018) In Rats And Mice" In Life Sciences, 1980, vol. 26, pp. 1453-1458.	
	DY	Jordan Craig V. "Antiestrogenic Action of Raloxifene and Tamoxifen: Today and Tomorrow" Journal of National Cancer Institute, Vol. 90, No. 13, July 1, 1998	
	DZ	Warri Anni. M. et al "Apoptosis in Toremifene Induced Growth Inhibition of Human Breast Cancer Cells in Vivo and In Vitro" Journal of National Cancer Institute, Vol. 85, No. 17, September 1, 1993	
	EA	Mobbs, B.G. et al "Concentration and Cellular Distribution of Androgen Receptor in Human Prostatic Neoplasia: Can Estrogen Treatment Increase Androgen Receptor Content?" J. Steroid Biochem. Vol. 19, No. 3 pp. 1279-1290, 1983.	

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box ?

+

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/747,686
		Filing Date	December 30, 2003
		First Named Inventor	STEINER, Mitchell S.
		Group Art Unit	1615
		Examiner Name	Not yet known
Sheet 9 of 9	Attorney Docket Number	P-2769-US9	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	EB	Krieg, Michael et al "Androgens and Estrogens: Their Interaction with Stroma and Epithelium of Human Benign Prostatic Hyperplasia and Normal Prostate" J. Steroid Biochem. Vol. 19, No. 1 pp. 155-161, 1983	
	EC	Hard, Gordon C. et al. "Major Difference in the Hepatocarcinogenicity and DNA Adduct Forming Ability between Toremifene and Tamoxifen in Female Crl: CD(BR) Rats" Cancer Research 53, 4534-4541, October 1, 1993	
	ED	Boyle Peter et al "Epidemiology of Prostate Cancer Chemoprevention" Eur Urol 1999: 35:370-376	
	EE	Bostwick, David G. et al "Reversibility of Prostatic Intraepithelial Neoplasia: Implications for Chemoprevention" Eur. Urol 1999: 35:492-495	
	EF	Bostwick David "Prospective Origins of Prostate Carcinoma" American Cancer Society 1996	
	EG	The Lancet "The Challenge of Breast Cancer" Vol. 342, September 18, 1993	
	EH	Zaridze, David G. et al "International Trends in Prostatic Cancer" Int. J. Cancer: 33, 223-230 (1984)	
	EI	Nevalainen MT et al "Hormone regulation of human prostate in organ culture" Cancer Res. 1993 Nov 1;53 (21):5199-207	

Examiner Signature	Date Considered
--------------------	-----------------

* **EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.